Pricing Log in Create free account
Saturday 7 November 2026 Export SEER’s income statement to Excel — free account

Seer, Inc.

SEER Healthcare Biotechnology

Seer, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, up 17.0% from fiscal 2024.

Revenue
−23.4%
EPS
+6.06%
Free cash flow
+36.7%

Quarter to June 2026, against a year earlier

1.64 0.01 +0.61%
Market cap
$90.3M
P/E
0.0×
Fwd P/E
−1.5×
Dividend yield
—
F-score
5/9
Altman Z
−0.55
Beneish M
−2.98
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.11
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — 2 — — 1 — 1 1 — — —
Insider Ownership 33.14%

Capital & Financial Ratios $m

Size
Market Cap 90.25
Revenue ttm 14.22
Net income ttm (67.96)
Free cash flow ttm (43.98)
Net debt Q (152.85)
Valuation
P/E 0.00
Forward P/E (1.53) (negative: loss-making)
Price / sales 6.36
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.40
Financial health
Current ratio Q 14.74 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (5.42)
Growth
Revenue growth Q −23.43% (below 0%: shrinking)
Operating income growth Q +17.97% (above 0%: growing)
EPS, this year +14.06%
EPS, next year A +3.95%
Revenue, next year A −2.88% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +12.08%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −4.4×, against a ten-year median of −4.7×; over the ten years it ranged from −13.6× in 2023 to 4,656× in 2021.
P/S against its own 10 years 7.12%
10-year low 10-year high
P/B against its own 10 years 30.68%
10-year low 10-year high
EV/FCF against its own 10 years 22.23%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 316 236 186 153
Receivables 7 6 6 3
Inventory 4 7 8 8
Other — — — —
331 253 202 166
2023 2024 2025 Q'26
Payables 1 5 6 3
ST’ Debt — — — —
Other 0 0 0 0
13 15 16 11

Compound Annual Growth %

10y 5y 3y
Sales — 90.78% 2.28%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (9.69%) (16.60%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY25 Estimate −0.39 Actual −0.33

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY24 −0.29 −0.34 Miss by 0.05
Q4 FY24 −0.40 −0.34 Beat by 0.06
Q1 FY25 −0.37 −0.34 Beat by 0.03
Q2 FY25 −0.39 −0.33 Beat by 0.06

EPS $

Mar Jun Sep Dec Year
’26 (0.30) (0.31) — — —
’25 (0.34) (0.33) (0.32) (0.29) (1.28)
’24 (0.32) (0.35) (0.35) (0.37) (1.39)
’23 (0.38) (0.37) (0.33) (0.28) (1.35)
’22 (0.38) (0.37) (0.38) (0.36) (1.49)
’21 (0.27) (0.27) (0.30) (0.32) (1.17)
’20 (0.61) (0.63) (0.80) (0.54) (2.48)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 3 3 — — —
’25 4 4 4 4 17
’24 3 3 4 4 14
’23 4 4 4 4 17
’22 3 4 4 5 15
’21 0 1 2 3 7
’20 0 0 0 0 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (15) (10) — — —
’25 (11) (15) (8) (11) (44)
’24 (10) (10) (14) (11) (46)
’23 (19) (15) (14) (10) (59)
’22 (19) (14) (13) (14) (61)
’21 (15) (10) (9) (12) (46)
’20 (5) (5) (5) (5) (21)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (16) (10) — — —
’25 (12) (15) (8) (11) (46)
’24 (11) (11) (16) (11) (49)
’23 (19) (16) (19) (12) (66)
’22 (20) (16) (16) (19) (71)
’21 (16) (12) (11) (14) (53)
’20 (6) (7) (6) (6) (25)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — 0 1 7 15 17 14 17 14 +128.7% 16 19 26 +16.0%
Gross margin, % — — 0.00 100.00 100.00 51.56 45.78 51.05 49.79 51.06 47.70 +51.1 pt
EBT — — (6) (16) (33) (71) (93) (86) (87) (73) (68) +42.0%
EBT margin, % — — 0.00 (13,825.86) (4,996.19) (1,075.55) (600.05) (517.84) (610.45) (442.75) (477.55) (442.7) pt
Net income — 0 (6) (16) (33) (71) (93) (86) (87) (74) (68) n/m
Per share, $
Per share, $ Revenue — — 0.00 0.02 0.05 0.11 0.25 0.26 0.23 0.29 0.26 n/m
Earnings — — (0.10) (2.31) (2.48) (1.17) (1.49) (1.35) (1.39) (1.28) (1.22) +43.9%
Cash flow — — (0.08) (1.88) (1.58) (0.76) (0.97) (0.93) (0.74) (0.77) (0.79) +39.2%
Capex — — 0.00 (0.59) (0.34) (0.11) (0.16) (0.11) (0.05) (0.02) (0.01) n/m
Free cash flow — — (0.08) (2.47) (1.92) (0.88) (1.14) (1.04) (0.79) (0.79) (0.80) +39.7%
Book value — — 0.49 12.61 32.66 8.26 7.16 6.22 5.25 4.51 4.09 +37.2%
Shares, m — — 61 7 13 61 62 64 62 57 56 (0.8%)
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — — — 1,536.28 2,044.75 209.81 23.57 7.43 10.16 6.34 6.36 548.3
P/B — — — 0.00 3.11 2.76 0.82 0.31 0.44 0.41 0.40 1.1
EV/Sales — — — 1,308.71 1,386.42 149.35 (3.61) (11.55) (6.52) (4.87) (4.39) 402.6
EV/FCF — — — (13.39) (35.86) (18.55) 0.79 2.90 1.87 1.77 1.42 (8.6)
Cash, $m
Cash, $m Operating cash flow — — (5) (13) (21) (46) (61) (59) (46) (44) (43) +38.1%
Capex — — 0 (4) (5) (7) (10) (7) (3) (1) (1) +31.6%
Free cash flow — — (5) (17) (25) (53) (71) (66) (49) (46) (44) +38.6%
Balance, $m
Balance, $m Working capital — — 28 83 425 398 422 317 238 186 155 +31.4%
Net debt — — (31) (86) (432) (400) (421) (316) (236) (186) (153) +29.2%
Shareholders’ equity — — 30 88 432 503 447 397 328 259 226 +36.1%
Returns, %
Returns, % ROA — — (37.43) (25.27) (12.24) (14.50) (18.10) (18.67) (21.57) (22.21) (23.47) +15.2 pt
ROIC — — 0.00 (636.04) 0.00 (43.44) (235.97) (80.15) (68.63) (66.40) (60.78) (66.4) pt
ROE — — 48.31 122.84 (15.94) (15.23) (19.57) (20.45) (23.91) (25.08) (26.45) (73.4) pt
People
People Employees — — — — 60 118 164 147 134 124 — +15.6%
Revenue/emp, $m — — — 0.00 0.01 0.06 0.09 0.11 0.11 0.13 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Seer, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
VANI Vivani Medical, Inc. $93.8M — (loss-making) — (loss-making) −71.87% (below 0%: shrinking) n/m +0.39% (above 0%: growing) 0.00% 0.00% Compare
VXRT VAXART, INC. $92.4M 2.8× — (loss-making) −85.33% (below 0%: shrinking) n/m −57.23% (below 0%: shrinking) 100.00% (162.74%) Compare
NMRA Neumora Therapeutics, Inc. $91.5M — (loss-making) — — n/m +24.45% (above 0%: growing) 0.00% 0.00% Compare
ICCC ImmuCell Corporation $90.4M 117× — (loss-making) +11.50% (above 0%: growing) +233.33% (above 0%: growing) +54.86% (above 0%: growing) 33.92% 26.93% Compare
SEER Seer, Inc. $90.3M — (loss-making) — (loss-making) −23.43% (below 0%: shrinking) n/m +36.73% (above 0%: growing) 48.55% (542.91%)
RTSN Retension Pharmaceuticals, Inc. $89.3M — — — — — — — Compare
CBUS Cibus, Inc. $87.1M — (loss-making) — (loss-making) +6.54% (above 0%: growing) n/m +31.62% (above 0%: growing) 100.00% (1,300.30%) Compare
PLYX Polaryx Therapeutics, Inc. $86.7M — (loss-making) — — n/m −93.09% (below 0%: shrinking) — 0.00% Compare
MIST Milestone Pharmaceuticals Inc. $86.2M — (loss-making) — (loss-making) −62.73% (below 0%: shrinking) n/m −80.81% (below 0%: shrinking) 94.28% (4,584.97%) Compare
Median of peers $89.8M — — −62.73% — +0.39% 64.10% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 28 May 2025

Chief executive’s pay

Year Total pay Actually paid $100 invested
2024 3.55m 4.58m 10.13
2023 5.20m (136.66k) 8.51
2022 6.74m (15.54m) 25.43

Ownership

Directors and executive officers, together 39.80%
Omid Farokhzad, M.D. 38.00%
SoftBank SB Global Advisers Limited 5.40%
aMoon Fund Growth Fund Limited Partnership 5.10%
Invus Public Equities, LP 4.40%
Radoff Bradley Louis 3.00%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Seer, Inc. (SEER) Latest News

2 Nov

Impact 3 · · Business Wire

29 Oct

Impact 3 · · GlobeNewswire

21 Oct

Impact 3 · · GlobeNewswire

23 Sep

Impact 4 · · GlobeNewswire

21 Sep

Impact 3 · · GlobeNewswire

16 Sep

Impact 3 ·

18 Aug

Impact 3 · · The Motley Fool transcript

13 Aug

Impact 4 ·

12 Aug

Impact 3 · · Moby transcript
Impact 3 · transcript

11 Aug

Impact 3 · · MarketBeat transcript
Impact 3 ·

30 Jul

Impact 4 ·

28 Jul

Impact 4 ·

22 Jul

Impact 4 ·

20 Jul

Impact 3 ·

17 Jul

Impact 4 ·

8 Jul

Impact 3 ·

6 Jul

Impact 4 ·
Impact 3 · · InvestorsHub

2 Jul

Impact 4 ·

1 Jul

Impact 3 ·

29 Jun

Impact 3 ·

24 Jun

Impact 3 · · Business Wire

22 Jun

Impact 3 · · GlobeNewswire

15 Jun

Impact 3 ·
Impact 3 ·

29 May

Impact 3 · · GlobeNewswire

27 May

Impact 3 · · Business Wire

14 May

Impact 4 · · Moby
stockrow.com/SEER · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com